津药药业：收到化学原料药上市申请批准通知书

Core Viewpoint - The company Tianyao Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Difluprednate, a topical corticosteroid drug that can inhibit inflammation caused by various irritants [1] Group 1: Product Information - Difluprednate is primarily available in the form of eye drops and is used to treat inflammation and pain associated with eye surgeries [1] - According to the IQVIA database, the global sales of Difluprednate formulations are projected to be $49 million in 2023 and $41 million in 2024 [1]